Fair Value Calculator Fair Value Calculator
EN DE

MGRB Fair Value & Analysis

US · Market cap $6.3B

M MGRB logo MGRB MGRB · US
Price$17.16
Fair Value$26.58
Upside+54.9%
Quality76/100
Watch MGRB for free, get notified when fair value or trend changes. Watch for free
Evidence: Medium Range $18.96 – $34.59

Fair value as of: Jun 24, 2026

From 26 valuation models · updated 21 days ago

Fair value updated Jun 24, 2026, revised from $26.92 to $26.58 (−1.3%) since Jun 23, 2026. Share price +2.1% over the past month.

Price vs Fair Value (12 months)

$18.00 $16.07 Fair Value $26.58 Jul 2025 Jul 2026

12‑month range $16.07 – $18.00 · fair‑value band $18.96 – $34.59 · the $17.16 price screens below the $26.58 fair value. As of Jun 24, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

MGRB (MGRB) currently trades at $17.16, while our model-based Fair Value estimate is $26.58, implying the stock looks roughly 54.9% undervalued today. We read business quality at 76/100 (high quality). Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

It earns a return on equity of 13.1%. Net debt stands at $2.1B. Fundamentals as of Jun 24, 2026

Our scenario range runs from $18.96 (bear case) to $34.59 (bull case); at $17.16, the current price sits below that range. The share trades about 5% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

Key figures & financial health

Return on equity 13.1%
Free cash flow $1.0B FY2025
Dividend yield 7.0%
Net debt $2.1B FY2025

Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

MGRB reported revenue of $2.4B in FY2025 versus $2.4B in FY2021, a compound +0.3%/yr. Reported net income was $717M in FY2025, compounding +6.1%/yr from FY2021.

Revenue +0.3%/yr
FY21 $2.4B
FY22 $2.3B
FY23 $2.1B
FY24 $2.0B
FY25 $2.4B
Net income +6.1%/yr
FY21 $566M
FY22 $1.1B
FY23 $673M
FY24 $512M
FY25 $717M

Is MGRB fairly valued? → Check now

📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog, it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "MGRB Fair Value". https://www.fairvalue-calculator.com/stock/MGRB

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is MGRB undervalued?
As of Jun 24, 2026, our model estimates a fair value of $26.58 versus a price of $17.16, about +55% (undervalued). Model-based estimate, not financial advice.
What is the fair value of MGRB?
Our model-based fair value for MGRB is $26.58 (as of Jun 24, 2026), built from audited fundamentals. The current price is $17.16.
What is the quality score of MGRB?
MGRB has a Quality Score of 76/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the net profit margin of MGRB?
The net profit margin of MGRB is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.
Does MGRB pay a dividend?
MGRB currently shows a dividend yield of about 6.99% relative to its recent price (as of Jun 24, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Unlock the full MGRB analysis, and try Pro free

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.